{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:42:52Z","timestamp":1780504972270,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"MSD Portugal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s41669-024-00552-0","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:29:07Z","timestamp":1739291347000},"page":"423-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal"],"prefix":"10.1007","volume":"9","author":[{"given":"Joana","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f3nia","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"552_CR1","unstructured":"International Agency for Research on Cancer (IARC). GLOBOCAN 2022 Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2022. Breast Cancer Fact Sheet. 2023; Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/20-breast-fact-sheet.pdf (accessed Oct 11, 2023)."},{"key":"552_CR2","unstructured":"Registo Oncol\u00f3gico Nacional, Registo Oncol\u00f3gico Nacional de Todos os Tumores na Popula\u00e7\u00e3o Residente em Portugal, em 2019. 2022."},{"issue":"2","key":"552_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247\u201369.","journal-title":"Arch Gynecol Obstet"},{"key":"552_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/469251","volume":"2014","author":"CA Parise","year":"2014","unstructured":"Parise CA, Caggiano V. Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014: 469251.","journal-title":"J Cancer Epidemiol"},{"issue":"4_Supplement","key":"552_CR5","doi-asserted-by":"publisher","first-page":"P6-08-08","DOI":"10.1158\/1538-7445.SABCS17-P6-08-08","volume":"78","author":"S Wong","year":"2018","unstructured":"Wong S, et al. Abstract P6\u201308-08: Age-Related differences in clinicopathologic features and survival amongst women with triple negative breast cancer: a population-based study. Cancer Res. 2018;78(4_Supplement):P6-08\u201308.","journal-title":"Cancer Res"},{"issue":"15 Pt 1","key":"552_CR6","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429\u201334.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"552_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/bjc.2017.379","volume":"118","author":"SM Reddy","year":"2018","unstructured":"Reddy SM, et al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer. 2018;118(1):17\u201323.","journal-title":"Br J Cancer"},{"issue":"22","key":"552_CR8","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin NU, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463\u201372.","journal-title":"Cancer"},{"issue":"5","key":"552_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40273-021-01121-7","volume":"40","author":"M Huang","year":"2022","unstructured":"Huang M, et al. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. Pharmacoeconomics. 2022;40(5):519\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"552_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.31914","volume":"144","author":"MC van Maaren","year":"2019","unstructured":"van Maaren MC, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2019;144(2):263\u201372.","journal-title":"Int J Cancer"},{"key":"552_CR11","doi-asserted-by":"crossref","unstructured":"Liu, Y.Y., T.J. Yu, and G.Y. Liu, The predictive value of the prognostic staging system in the 8th edition of the American Joint Committee on Cancer for triple-negative breast cancer: a SEER population-based analysis. Future Oncol, 2019. 15(4): p. 391-400.","DOI":"10.2217\/fon-2018-0145"},{"issue":"1","key":"552_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12885-017-3969-y","volume":"18","author":"SAM Urru","year":"2018","unstructured":"Urru SAM, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer. 2018;18(1):56.","journal-title":"BMC Cancer"},{"issue":"7","key":"552_CR13","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1245\/s10434-014-3546-4","volume":"21","author":"L Steward","year":"2014","unstructured":"Steward L, et al. Predictive factors and patterns of recurrence in patients with triple negative breast cancer. Ann Surg Oncol. 2014;21(7):2165\u201371.","journal-title":"Ann Surg Oncol"},{"key":"552_CR14","unstructured":"Registo Oncol\u00f3gico Nacional, Registo Oncol\u00f3gico Nacional de Todos os Tumores na Popula\u00e7\u00e3o Residente em Portugal, em 2018. 2021."},{"key":"552_CR15","unstructured":"Registo Oncol\u00f3gico Regional do Norte, Registo Oncol\u00f3gico Nacional 2010. 2016."},{"key":"552_CR16","unstructured":"Sociedade Portuguesa de Oncologia, Manual de Oncologia SPO: Abordagem e tratamento do cancro da mama. 2020."},{"key":"552_CR17","unstructured":"Global Burden of Disease Collaborative Network, Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. 2021."},{"issue":"10258","key":"552_CR18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"key":"552_CR19","unstructured":"World Health Organization. Disability-adjusted life years (DALYs). 2023; Available from: https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/158(accessed Oct 11, 2023)."},{"issue":"3","key":"552_CR20","first-page":"429","volume":"72","author":"CJ Murray","year":"1994","unstructured":"Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429\u201345.","journal-title":"Bull World Health Organ"},{"issue":"9859","key":"552_CR21","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)61899-6","volume":"380","author":"CJL Murray","year":"2012","unstructured":"Murray CJL, et al. GBD 2010: design, definitions, and metrics. The Lancet. 2012;380(9859):2063\u20136.","journal-title":"The Lancet"},{"key":"552_CR22","unstructured":"Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. 2019; Available from: https:\/\/ghdx.healthdata.org\/record\/ihme-data\/global-burden-disease-study-2019-gbd-2019-reference-life-table (accessed Jun 05, 2023)."},{"key":"552_CR23","unstructured":"Portaria n.\u00ba 254\/2018 de 7 de setembro do Minist\u00e9rio da Sa\u00fade. Di\u00e1rio da Rep\u00fablica: 1\u00aa s\u00e9rie, N.\u00ba 173. 2018."},{"key":"552_CR24","doi-asserted-by":"crossref","unstructured":"Portaria n.\u00ba 207\/2017 de 11 de julho do Minist\u00e9rio da Sa\u00fade. Di\u00e1rio da Rep\u00fablica: 1\u00aa s\u00e9rie, N.\u00ba 132. 2017. .","DOI":"10.22420\/rde.v11i20.774"},{"key":"552_CR25","unstructured":"Barros, P., et al., Pol\u00edticas P\u00fablicas em Sa\u00fade: 2011 \u2013 2014 Avalia\u00e7\u00e3o do Impacto. 2015."},{"key":"552_CR26","unstructured":"Servi\u00e7os Partilhados do Minist\u00e9rio da Sa\u00fade, Cat\u00e1logo. 2023."},{"key":"552_CR27","unstructured":"Becker, G. Human Capital: A Theoretical and Empirical Analysis, with Special Reference to Education, Second Edition. 1975: National Bureau of Economic Research, Inc."},{"key":"552_CR28","unstructured":"Instituto Nacional de Estat\u00edstica. Popula\u00e7\u00e3o residente (N.\u00ba) por Local de resid\u00eancia (NUTS - 2013), Sexo e Idade; Anual - INE, Estimativas anuais da popula\u00e7\u00e3o residente. 2023a; Available from: https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0007307&contexto=bd&selTab=tab2&xlang=pt (accessed Jan 03, 2023)."},{"key":"552_CR29","unstructured":"Instituto Nacional de Estat\u00edstica. Popula\u00e7\u00e3o empregada (N.\u00ba) por Local de resid\u00eancia (\u00e0 data dos Censos 2021), Sexo, Grupo et\u00e1rio e N\u00edvel de escolaridade mais elevado completo. 2023b; Available from: https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0011698&contexto=bd&selTab=tab2 (accessed Jan 03, 2023)."},{"key":"552_CR30","unstructured":"Comiss\u00e3o para a Cidadania e a Igualdade de G\u00e9nero, Igualdade de G\u00e9nero em Portugal 2021: Trabalho e Emprego. 2021."},{"key":"552_CR31","unstructured":"Instituto Nacional de Estat\u00edstica. Popula\u00e7\u00e3o activa (S\u00e9rie 2021 - N.\u00ba) por Local de resid\u00eancia (NUTS - 2013), Sexo, Grupo et\u00e1rio e N\u00edvel de escolaridade mais elevado completo; Anual - INE, Inqu\u00e9rito ao emprego (S\u00e9ries - 2021). 2023c; Available from: https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0007307&contexto=bd&selTab=tab2&xlang=pt (accessed Jan 03, 2023)."},{"issue":"3","key":"552_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.20344\/amp.4784","volume":"27","author":"MR Andr\u00e9","year":"2014","unstructured":"Andr\u00e9 MR, et al. Breast cancer patients survival and associated factors: reported outcomes from the Southern Cancer Registry in Portugal. Acta Med Port. 2014;27(3):325\u201330.","journal-title":"Acta Med Port"},{"key":"552_CR33","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS). Mortalidade em Portugal - Dashboard da mortalidade dos residentes em Portugal. 2023; Available from: https:\/\/app.powerbi.com\/view?r=eyJrIjoiZjE5ZDhiYjQtZTY4Yi00NTg2LWE5MWQtNmViODliZDYyNDBhIiwidCI6IjIyYzg0NjA4LWYwMWQtNDZjNS04MDI0LTYzY2M5NjJlNWY1MSIsImMiOjh9 (accessed Jun 05, 2023)."},{"issue":"7","key":"552_CR34","doi-asserted-by":"publisher","first-page":"A724","DOI":"10.1016\/j.jval.2016.09.2161","volume":"19","author":"R Sousa","year":"2016","unstructured":"Sousa R, et al. Cost and burden of female breast cancer in Portugal. Value in Health. 2016;19(7):A724.","journal-title":"Value in Health"},{"issue":"6","key":"552_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000984","volume":"5","author":"M Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o M, et al. Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype. ESMO Open. 2020;5(6): e000984.","journal-title":"ESMO Open"},{"key":"552_CR36","first-page":"765","volume":"11","author":"JM Lopes","year":"2017","unstructured":"Lopes JM, et al. The cost of cancer treatment in Portugal. Ecancermedicalscience. 2017;11:765.","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"552_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40273-020-00993-5","volume":"39","author":"M Neves","year":"2021","unstructured":"Neves M, et al. Multiple myeloma in Portugal: burden of disease and cost of illness. Pharmacoeconomics. 2021;39(5):579\u201387.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"552_CR38","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/j.jval.2022.09.534","volume":"25","author":"S Miguel","year":"2022","unstructured":"Miguel S, et al. EE287 indirect costs of multiple myeloma in Portugal. Value Health. 2022;25(12):S110.","journal-title":"Value Health"},{"issue":"4","key":"552_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000525206","volume":"30","author":"F Magro","year":"2022","unstructured":"Magro F, et al. Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal. GE Portuguese J Gastroenterol. 2022;30(4):283\u201392.","journal-title":"GE Portuguese J Gastroenterol"},{"issue":"1","key":"552_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.repc.2014.08.005","volume":"34","author":"M Gouveia","year":"2015","unstructured":"Gouveia M, et al. Burden of disease and cost of illness of atrial fibrillation in Portugal. Rev Port Cardiol. 2015;34(1):1\u201311.","journal-title":"Rev Port Cardiol"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00552-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:59:00Z","timestamp":1745855940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00552-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00552-0","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"17 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was developed by IQVIA Portugal and supported by MSD Portugal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gabriela Sousa, Lu\u00eds Costa, Margarida Brito and S\u00f3nia Oliveira received honoraria from MSD Portugal for participation in the expert panel. Bernardo Rodrigues, Jo\u00e3o Ferreira and Joana Silva are employees of MSD Portugal. Margarida Borges and Lu\u00eds Silva Miguel are employees of IQVIA Portugal and were contracted by MSD Portugal to conduct this study. S\u00f3nia Oliveira has served as a consultant to Novartis, Pfizer, Eli Lilly Nederland, AstraZeneca, Daiichi Sankyo, Gilead, MSD and Seagen; has received research funding from Pfizer; and has received accommodation services from Novartis, Pfizer, Daiichi Sankyo, Astellas, Bristol-Myers Squibb, AstraZeneca and Gilead. Lu\u00eds Costa has received grants\/research support from Eli Lilly Nederland, MSD, Roche and Amgen; has received honoraria from Servier, AstraZeneca and MSD; and has participated in a sponsored speaker bureau of Novartis, Pfizer, Eli Lilly Nederland, MSD and AstraZeneca. None of the other authors have declared any conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Gabriela Sousa, Lu\u00eds Costa, Margarida Brito and S\u00f3nia Oliveira participated in the expert panel, provided useful insights for this study and reviewed the final article. Bernardo Rodrigues, Jo\u00e3o Ferreira and Joana Silva were responsible for the article development and revision. Margarida Borges and Lu\u00eds Silva Miguel were responsible for model development, expert panel moderation, data collection and analysis, and article development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All the data analysed were anonymous; therefore, the authors declare that no patient data appear in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants included in the EP provided their informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants included in the EP provided their consent for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data supporting the findings are available within the article and supplementary material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}